Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week [Yahoo! Finance]
Monopar Therapeutics Inc. (MNPR)
Company Research
Source: Yahoo! Finance
A total of 5 investors have a majority stake in the company with 51% ownership Insider ownership in Monopar Therapeutics is 12% To get a sense of who is truly in control of Monopar Therapeutics Inc. ( NASDAQ:MNPR ), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 44% to be precise, is individual investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Clearly, individual investors benefitted the most after the company's market cap rose by US$40m last week. Let's take a closer look to see what the different types of shareholders can tell us about Monopar Therapeutics. See our latest analysis for Monopar Therapeutics Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most
Show less
Read more
Impact Snapshot
Event Time:
MNPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNPR alerts
High impacting Monopar Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
MNPR
News
- Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar TherapeuticsPR Newswire
- Monopar Therapeutics Inc. (NASDAQ: MNPR) had its price target raised by analysts at HC Wainwright from $22.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Monopar Therapeutics files to sell 882,761 shares of common stock for holders [Seeking Alpha]Seeking Alpha
- Monopar Therapeutics Inc. (NASDAQ: MNPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $72.00 price target on the stock.MarketBeat
- Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded WarrantsGlobeNewswire
MNPR
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form SCHEDULE
- 2/12/25 - Form SCHEDULE
- MNPR's page on the SEC website